Show simple item record

dc.contributor.authorNorvoll Magnussen, Synnøve
dc.contributor.authorToraskar, Jimita Prashant
dc.contributor.authorHadler-Olsen, Elin Synnøve
dc.contributor.authorSteigedal, Tonje S.
dc.contributor.authorSvineng, Gunbjørg
dc.date.accessioned2021-04-15T07:11:35Z
dc.date.available2021-04-15T07:11:35Z
dc.date.created2021-02-25T12:17:24Z
dc.date.issued2021
dc.identifier.citationCancers. 2021, 13:959 (5), 1-13.en_US
dc.identifier.issn2072-6694
dc.identifier.urihttps://hdl.handle.net/11250/2737840
dc.description.abstractThe extracellular matrix protein nephronectin plays an important regulatory role during embryonic development, controlling renal organogenesis through integrin α8β1 association. Nephronectin has three main domains: five N-terminal epidermal growth factor-like domains, a linker region harbouring two integrin-binding motifs (RGD and LFEIFEIER), and a C-terminal MAM domain. In this review, we look into the domain-related functions of nephronectin, and tissue distribution and expression. During the last two decades it has become evident that nephronectin also plays a role during cancer progression and in particular metastasis. Nephronectin is overexpressed in both human and mouse breast cancer compared to normal breast tissue where the protein is absent. Cancer cells expressing elevated levels of nephronectin acquire increased ability to colonise distant organs. In particular, the enhancer-motif (LFEIFEIER) which is specific to the integrin α8β1 association induces viability via p38 MAPK and plays a role in colonization. Integrins have long been desired as therapeutic targets, where low efficiency and receptor redundancy have been major issues. Based on the summarised publications, the enhancer-motif of nephronectin could present a novel therapeutic target.en_US
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleNephronectin as a matrix effector in canceren_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber1-13en_US
dc.source.volume13:959en_US
dc.source.journalCancersen_US
dc.source.issue5en_US
dc.identifier.doi10.3390/cancers13050959
dc.identifier.cristin1893648
dc.description.localcodeCopyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal